AstraZeneca expects its antibody cocktail to work in the new COVID variant
[ad_1]
LONDON (Reuters) – AstraZeneca (NASDAQ 🙂 said on Friday it was hoped that antibody cocktails against COVID-19 would remain effective in the face of a new variant spreading in South Africa, and that the variant was being resistant to its vaccine.
“As with any new variant being vaccinated, we are looking at B.1.1.529 to understand more about this and the impact on the vaccine,” AstraZeneca said in a statement, adding that research was being conducted in Botswana and Eswatinin.
“Furthermore, we are testing the long-acting antibody combination AZD7442 against this new variant and hope that it will maintain the efficacy of AZD7442 as there are two potent antibodies with different and complementary antiviral activities.”
Fusion Media or anyone involved with Fusion Media will not be liable for any loss or damage as a result of relying on the information contained in the data, estimates, charts and buy / sell signals contained on this website. Please be fully informed about the risks and costs associated with trading in the financial markets, which is one of the most risky forms of investment possible.
[ad_2]
Source link
